NCT06652243 - Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL

SN301A

"SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles."

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai